Related Experiment Video
Updated: Jan 23, 2026

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of
Elena Priante1, Elena Tavella2, Elisa Girardi3
1Department of Woman's and Child's Health, Unit of Neonatal Intensive Care, University of Padua, Padua, Italy.
Insights
New Italian guidelines restricting palivizumab for premature infants significantly increased respiratory syncytial virus hospitalizations. This study highlights the need to re-evaluate palivizumab coverage for preventing RSVH in vulnerable infants.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Public Health Policy
Background:
- Premature infants face the highest risk of respiratory syncytial virus (RSV) infections.
- Palivizumab is the sole licensed prophylaxis for RSV hospitalization (RSVH) in infants born before 35 weeks gestational age (wGA).
- In 2016, Italian drug agency (AIFA) restricted palivizumab reimbursement, excluding infants born after 29 wGA.
Purpose of the Study:
- To compare the incidence of RSVH in premature infants before and after AIFA's 2016 policy change on palivizumab eligibility.
- To assess the impact of restricted palivizumab access on RSVH rates in neonatal intensive care units (NICUs).
Main Methods:
- A retrospective cohort study involving 536 infants born between 29 and 35 wGA across three NICUs in northern Italy.
- Data collected via electronic medical records and parental interviews, comparing two consecutive RSV seasons (2015-2016 vs. 2016-2017).
- Analysis focused on RSVH rates, palivizumab administration, and hospitalizations for other respiratory viruses.
Main Results:
- RSVH incidence rose significantly from 1.9% in the pre-policy season to 5.1% in the post-policy season (OR=2.77, p=0.045).
- Among infants not receiving palivizumab, RSVH rates increased from 1.8% to 5.9% (OR=3.42, p=0.045).
- Hospital admissions for respiratory viruses other than RSV showed no significant difference between the two seasons.
Conclusions:
- Restricting palivizumab reimbursement led to a significant increase in RSVH among eligible infants.
- The policy change did not affect hospitalizations for other respiratory viruses, suggesting a specific impact on RSV.
- Future palivizumab coverage decisions should prioritize cost-benefit analyses considering RSVH prevention in high-risk infants.
Objective:
Premature infants have the highest risk of being hospitalized with respiratory syncytial virus (RSV) infections. Palivizumab is the only licensed agent for RSVhospitalization (RSVH) prophylaxis in infants born at < 35 weeks of gestational age (wGA). In 2016, the Italian Drug Agency (Agenzia Italiana del Farmaco [AIFA]) has restricted the eligibility for reimbursement to infants at high risk of RSVH, ruling out palivizumab administration for infants born at > 29 wGA. The aim of the present study was to compare the incidence of RSVH in two consecutive epidemic seasons (2015-2016 vs. 2016-2017), that is, before and after the new AIFA recommendations on palivizumab eligibility.
Study Design:
This was a noninterventional retrospective cohort study conducted at three neonatal intensive care units (NICUs) in northern Italy. Infants born at 29 and 35 wGA between March 15, 2015 and March 14, 2017 were enrolled for this study. Electronic medical charts were reviewed and parents were interviewed by telephone. Data were collected on neonatal course during NICU stay, palivizumab administration, and hospitalizations related to respiratory infections during the 1st year of life, comparing the infants born in season 1 with season 2.
Results:
Of 632 eligible infants, data were available for 536 (262 in season 1 and 274 in season 2). Overall, RSVH occurred 1.9 and 5.1% in infants in seasons 1 and 2, respectively (odds ratio [OR] = 2.77; 95% confidence interval [CI]: 0.98-7.8, p = 0.045). When the analysis was limited to patients not exposed to palivizumab, RSVHs were recorded for 1.8 and 5.9% infants in seasons 1 and 2, respectively (OR = 3.42; 95% CI: 0.96-12.20, p = 0.045). It is noteworthy that the incidence of hospital admissions for respiratory viruses other than RSV did not differ between the two seasons.
Conclusion:
Restricting eligibility for palivizumab reimbursement led to a significant increase in RSVH but had no impact on hospitalizations for other respiratory viruses. Future decisions on palivizumab prescription and coverage rules should be driven by a careful assessment of the cost-benefit ratio.
Related Concept Videos
Hospitals-II
Nurses that work in...
The Born-Haber Cycle
Hospitals-I
Diabetes Mellitus: Type 2 and Gestational
Restriction Enzymes
The host bacteria protect their own genomic DNA from these enzymes by methylating these sites. Some...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

